4 July 2024 - CSL Behring today announced that two haemophilia B patients were treated with the gene therapy Hemgenix ...
4 July 2024 - Referred by the Ministry of Health, the High Authority for Health has assessed the opportunity to integrate ...
24 June 2024 - Committed to a process of continuous development of its methods, the High Authority of Health is launching ...
1 March 2024 - A few months before the EU HTA regulation came into force, a delegation from the French HTA ...
13 December 2023 - CSL Behring has been granted Direct Access for Hemgenix (etranacogene dezaparvovec) by the French Ministry of ...
5 October 2023 - L’Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), the national authority for ...
17 August 2023 - The Health Technology Assessment of medicines is performed separately at the country level with some differences, but ...
8 August 2023 - While patient participation in individual health technology assessments has been frequently described in the literature, patient and ...
8 February 2023 - Santhera Pharmaceuticals announces that it has secured a final reimbursement agreement with the French authorities related to ...
24 January 2023 - Osteoporosis is a disease whose first cause is ageing and which is characterised by the reduction ...
30 November 2022 - Albireo Pharma today announced that the Committee Economic Health Products has approved reimbursed access to Bylvay (odevixibat) ...
5 September 2022 - The EMA has just modified the marketing authorisations granted to messenger RNA vaccines developed by Moderna and ...
8 July 2022 - Faced with the spread of the Monkeypox virus, the kinetics of the epidemic and the difficulties of ...
29 April 2022 - After authorising early access to Xevudy (sotrovimab) as a curative treatment for COVID-19 on 6 January, HAS ...
25 April 2022 - After authorising early access to Paxlovid for the treatment of COVID-19 on January 22, HAS assessed ...